BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 1087182)

  • 1. Biochemical and pharmacokinetic effects of leucovorin after high-dose methotrexate in a murine leukemia model.
    Sirotnak FM; Donsbach RC; Moccio DM; Dorick DM
    Cancer Res; 1976 Dec; 36(12):4679-86. PubMed ID: 1087182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue pharmacokinetics, inhibition of DNA synthesis and tumor cell kill after high-dose methotrexate in murine tumor models.
    Sirotnak FM; Donsbach RC; Dorick DM; Moccio DM
    Cancer Res; 1976 Dec; 36(12):4672-8. PubMed ID: 1000510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models.
    Sirotnak FM; Moccio DM; Dorick DM
    Cancer Res; 1978 Feb; 38(2):345-53. PubMed ID: 304375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of methotrexate polyglutamates in L1210 murine leukemia cells.
    Whitehead VM
    Cancer Res; 1977 Feb; 37(2):408-12. PubMed ID: 832265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of folate analogue transport inward in L1210 cells during methotrexate therapy of leukemic mice: evidence of the nature of the effect, possible host mediation, and pharmacokinetic significance.
    Sirotnak FM; Poser RE; Barrueco JR
    Cancer Res; 1987 Oct; 47(20):5334-9. PubMed ID: 3498533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Further evidence for a basis of selective activity and relative responsiveness during antifolate therapy of murine tumors.
    Sirotnak FM; Donsback RC
    Cancer Res; 1975 Jul; 35(7):1737-44. PubMed ID: 1169115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of reduced folate changes to inhibition of DNA synthesis induced by methotrexate in L1210 cells in vivo.
    Priest DG; Bunni M; Sirotnak FM
    Cancer Res; 1989 Aug; 49(15):4204-9. PubMed ID: 2743307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose methotrexate therapy with citrovorum factor: a pharmacologic perspective in murine tumor models.
    Sirotnak FM; Donsbach RC; Dorick DM; Moccio DM
    Cancer Treat Rep; 1977 Jul; 61(4):565-74. PubMed ID: 301778
    [No Abstract]   [Full Text] [Related]  

  • 9. Differential synthesis of methotrexate polyglutamates in normal proliferative and neoplastic mouse tissues in vivo.
    Poser RG; Sirotnak FM; Chello PL
    Cancer Res; 1981 Nov; 41(11 Pt 1):4441-6. PubMed ID: 6171339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic basis for differences in methotrexate sensitivity of normal proliferative tissues in the mouse.
    Sirotnak FM; Moccio DM
    Cancer Res; 1980 Apr; 40(4):1230-4. PubMed ID: 7357552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifolate polyglutamylation and competitive drug displacement at dihydrofolate reductase as important elements in leucovorin rescue in L1210 cells.
    Matherly LH; Barlowe CK; Goldman ID
    Cancer Res; 1986 Feb; 46(2):588-93. PubMed ID: 2416428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved therapeutic index with high-dose methotrexate: comparison of thymidine-purine rescue with citrovorum factor rescue in mice.
    Samuels LL; Straw JA
    Cancer Res; 1984 Jun; 44(6):2278-84. PubMed ID: 6609764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues.
    Chabner BA; Young RC
    J Clin Invest; 1973 Aug; 52(8):1804-11. PubMed ID: 4719662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism and selective effects of 1-beta-D-arabinofuranosylcytosine in L1210 and Host tissues in vivo.
    Chou TC; Hutchinson DJ; Schmid FA; Philips FS
    Cancer Res; 1975 Jan; 35(1):225-36. PubMed ID: 1109791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical and pharmacologic study of therapeutic synergism with cyclophosphamide plus methotrexate in murine L1210 leukemia.
    Klubes P; Cerna I
    Cancer Treat Rep; 1981; 65(1-2):107-14. PubMed ID: 7226161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative biochemical aspects of low and high doses of methotrexate in mice.
    Zaharko DS; Fung WP; Yang KH
    Cancer Res; 1977 Jun; 37(6):1602-7. PubMed ID: 870175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Markedly improved efficacy of edatrexate compared to methotrexate in a high-dose regimen with leucovorin rescue against metastatic murine solid tumors.
    Sirotnak FM; Otter GM; Schmid FA
    Cancer Res; 1993 Feb; 53(3):587-91. PubMed ID: 8425192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of methotrexate on the leukemic cell cycle in mouse ascitic leukemia L1210].
    Goncharova SA; Frankfurt OS
    Tsitologiia; 1975 Sep; 17(9):1051-6. PubMed ID: 1166521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of high-dose methotrexate and leucovorin on murine hemopoietic stem cells.
    Pannacciulli I; Massa G; Bogliolo G; Ghio R; Sobrero A
    Cancer Res; 1982 Feb; 42(2):530-4. PubMed ID: 6976827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of "early" thymidine/inosine protection as an adjunct to methotrexate therapy.
    Eleff M; Franks PE; Wampler GL; Collins JM; Goldman ID
    Cancer Treat Rep; 1985; 69(7-8):867-74. PubMed ID: 2410122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.